Lv1
10 积分 2025-05-28 加入
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
2个月前
已完结
From bench to bedside: Synthetic strategies and clinical application of PARP inhibitors
7个月前
已完结
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
8个月前
已完结
Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of view
1年前
已完结
皖公网安备34019202002308
